SM
RNTX

Senvest Management’s Rein Therapeutics RNTX Stock Holding History

Senvest Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300K Hold
230,895
– – 0.01% 49
2025
Q4 		$268K Hold
230,895
– – 0.01% 52
2025
Q3 		$264K Hold
230,895
– – 0.01% 52
2025
Q2 		$323K Hold
230,895
– – 0.01% 53
2025
Q1 		$409K Hold
230,895
– – 0.02% 42
2024
Q4 		$531K Hold
230,895
– – 0.02% 58
2024
Q3 		$801K Hold
230,895
– – 0.03% 49
2024
Q2 		$576K Hold
230,895
– – 0.02% 47
2024
Q1 		$1.3M Buy
+230,895
New +$1.11M 0.05% 51

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Senvest Management's RNTX Position: Q1 2026 in Review

Senvest Management held its Rein Therapeutics (RNTX) position steady in Q1 2026 at 230,895 shares worth $300K. The position accounts for 0.01% of the portfolio, ranked #49.

Senvest Management first reported a position in RNTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.3M in Q1 2024. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Senvest Management held 230,895 shares of Rein Therapeutics worth $300K as of Q1 2026.
  • Senvest Management left its Rein Therapeutics share count unchanged in Q1 2026.
  • Rein Therapeutics made up 0.01% of Senvest Management's portfolio in Q1 2026, its #49 holding.
  • Senvest Management first reported a position in Rein Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Senvest Management's Rein Therapeutics position peaked at $1.3M in Q1 2024.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Senvest Management's 13F filing for Q1 2026, filed 14 May 2026.